Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Evotec AG. (7/8/13). "Press Release: Evotec to Realign Discovery Chemistry Operations". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
  Organisation 2 Evotec (India) Pvt. Ltd. (RSIPL)
  Group Evotec (Group)
Products Product combinatorial chemistry
  Product 2 drug discovery services
Person Person Polywka, Mario (Evotec 201201–201812 COO RETIRED 12/18)
     


Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility, answering to an increasing requirement to operate closer to the principal R&D laboratories of our major customers. All project work in Thane will be finished at the end of September and Evotec (India) Private Ltd will be wound down from then.

As a consequence 120 people will have to leave the company and Evotec will take a one-time impairment charge of up to EUR 4 m in Q3 2013. At the same time Evotec confirms its revenue, profitability and cash guidance for 2013.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'Evotec were due to relocate its Indian chemistry operations in June 2014. During the due diligence in finding a new facility and because of growing customer requirements for European-based activities we came to the conclusion to exit our operations in India completely. Through this realignment we will be able to most efficiently serve our customers, utilise our UK chemistry resources and capabilities and also realise some cost savings. Unfortunately the impact is that we must say goodbye to a first-class work force in Thane that has so ably supported our customers over the last four years. I would like to express our sincere gratitude to these employees and wish them all the best for the future.'


ABOUT THE EVOTEC (INDIA) PRIVATE LIMITED

Evotec (India) Private Limited is a 100% subsidiary of Evotec AG. Its offering includes custom synthesis, process research and development, scale-up and analytical services.


FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top